In silico clinical trial evaluating lisdexamfetamine's and methylphenidate's mechanism of action computational models in an attention-deficit/hyperactivity disorder virtual patients' population. Front Psychiatry. 2023 Jun 2;14:939650. doi: 10.3389/fpsyt.2023.939650. PMID: 37333910; PMCID: PMC10273406. F.I.: 4,16 Q2

Inicio Repositorio In silico clinical trial evaluating lisdexamfetamine’s and methylphenidate’s mechanism of action computational models in an attention-deficit/hyperactivity disorder virtual patients’ population. Front Psychiatry. 2023 Jun 2;14:939650. doi: 10.3389/fpsyt.2023.939650. PMID: 37333910; PMCID: PMC10273406. F.I.: 4,16 Q2

2023/06

In silico clinical trial evaluating lisdexamfetamine’s and methylphenidate’s mechanism of action computational models in an attention-deficit/hyperactivity disorder virtual patients’ population. Front Psychiatry. 2023 Jun 2;14:939650. doi: 10.3389/fpsyt.2023.939650. PMID: 37333910; PMCID: PMC10273406. F.I.: 4,16 Q2

Autores/as:

Gutiérrez-Casares JR, Quintero J, Segú-Vergés C, Rodríguez Monterde P, Pozo-Rubio T, Coma M, Montoto C

Servicio:

Unidad Ambulatoria de Psiquiatría y Salud Mental de la Infancia, Niñez y Adolescencia (HPS)

Tipo:

Artículo

Materia:

https://pubmed.ncbi.nlm.nih.gov/37333910/

info@areasaludbadajoz.com

Contacto

Salud

Información

Ciudadanos

info@areasaludbadajoz.com

Contacto

Salud​

Información​

Ciudadanos​

Salud

Información

Ciudadanos